Anti SARS-CoV-2 Monoclonal Antibodies in Pre-Exposure or Post-Exposure in No- or Weak Responder to Vaccine Kidney Transplant Recipients: Is One Strategy Better than Another?
<b>Background:</b> Kidney transplant recipients (KTRs) are likely to develop severe COVID-19 and are less well-protected by vaccines than immunocompetent subjects. Thus, the use of neutralizing anti–SARS-CoV-2 monoclonal antibodies (mAbs) to confer a passive immunity appears attractive i...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-02-01
|
| Series: | Viruses |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4915/16/3/381 |
| _version_ | 1797239132283469824 |
|---|---|
| author | Anais Romero Charlotte Laurent Ludivine Lebourg Veronique Lemée Mélanie Hanoy Frank Le Roy Steven Grange Mathilde Lemoine Dominique Guerrot Dominique Bertrand |
| author_facet | Anais Romero Charlotte Laurent Ludivine Lebourg Veronique Lemée Mélanie Hanoy Frank Le Roy Steven Grange Mathilde Lemoine Dominique Guerrot Dominique Bertrand |
| author_sort | Anais Romero |
| collection | DOAJ |
| description | <b>Background:</b> Kidney transplant recipients (KTRs) are likely to develop severe COVID-19 and are less well-protected by vaccines than immunocompetent subjects. Thus, the use of neutralizing anti–SARS-CoV-2 monoclonal antibodies (mAbs) to confer a passive immunity appears attractive in KTRs. <b>Methods:</b> This retrospective monocentric cohort study was conducted between 1 January 2022 and 30 September 2022. All KTRs with a weak antibody response one month after three doses of mRNA vaccine (anti spike IgG < 264 (BAU/mL)) have received tixagevimab-cilgavimab in pre-exposure (group 1), post-exposure (group 2) or no specific treatment (group 3). We compared COVID-19 symptomatic hospitalizations, including intensive care unit hospitalizations, oxygen therapy, and death, between the three groups. <b>Results:</b> A total of 418 KTRs had SARS-CoV-2 infection in 2022. During the study period, we included 112 KTRs in group 1, 40 KTRs in group 2, and 27 KTRs in group 3. The occurrence of intensive care unit hospitalization, oxygen therapy, and COVID-19 death was significantly increased in group 3 compared to group 1 or 2. In group 3, 5 KTRs (18.5%) were admitted to the intensive care unit, 7 KTRs (25.9%) needed oxygen therapy, and 3 KTRs (11.1%) died. Patients who received tixagevimab-cilgavimab pre- or post-exposure had similar outcomes. <b>Conclusions:</b> This retrospective real-life study supports the relative effectiveness of tixagevimab-cilgavimab on COVID-19 infection caused by Omicron, used as a pre- or post-exposure therapy. The continued evolution of Omicron variants has made tixagevimab-cilgavimab ineffective and reinforces the need for new therapeutic monoclonal antibodies for COVID-19 active on new variants. |
| first_indexed | 2024-04-24T17:46:40Z |
| format | Article |
| id | doaj.art-e18e49b10bdd4f27bdf9d70144ce1275 |
| institution | Directory Open Access Journal |
| issn | 1999-4915 |
| language | English |
| last_indexed | 2024-04-24T17:46:40Z |
| publishDate | 2024-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Viruses |
| spelling | doaj.art-e18e49b10bdd4f27bdf9d70144ce12752024-03-27T14:07:43ZengMDPI AGViruses1999-49152024-02-0116338110.3390/v16030381Anti SARS-CoV-2 Monoclonal Antibodies in Pre-Exposure or Post-Exposure in No- or Weak Responder to Vaccine Kidney Transplant Recipients: Is One Strategy Better than Another?Anais Romero0Charlotte Laurent1Ludivine Lebourg2Veronique Lemée3Mélanie Hanoy4Frank Le Roy5Steven Grange6Mathilde Lemoine7Dominique Guerrot8Dominique Bertrand9Department of Nephrology and Hemodialysis, Hôpital de la Croix Rouge, 76230 Bois Guillaume, FranceDepartment of Nephrology, Transplantation and Hemodialysis, 1 Rue de Germont, Rouen University Hospital, 76000 Rouen, FranceDepartment of Nephrology, Transplantation and Hemodialysis, 1 Rue de Germont, Rouen University Hospital, 76000 Rouen, FranceDepartment of Virology, Rouen University Hospital, 76000 Rouen, FranceDepartment of Nephrology, Transplantation and Hemodialysis, 1 Rue de Germont, Rouen University Hospital, 76000 Rouen, FranceDepartment of Nephrology, Transplantation and Hemodialysis, 1 Rue de Germont, Rouen University Hospital, 76000 Rouen, FranceDepartment of Nephrology, Transplantation and Hemodialysis, 1 Rue de Germont, Rouen University Hospital, 76000 Rouen, FranceDepartment of Nephrology, Transplantation and Hemodialysis, 1 Rue de Germont, Rouen University Hospital, 76000 Rouen, FranceDepartment of Nephrology, Transplantation and Hemodialysis, 1 Rue de Germont, Rouen University Hospital, 76000 Rouen, FranceDepartment of Nephrology, Transplantation and Hemodialysis, 1 Rue de Germont, Rouen University Hospital, 76000 Rouen, France<b>Background:</b> Kidney transplant recipients (KTRs) are likely to develop severe COVID-19 and are less well-protected by vaccines than immunocompetent subjects. Thus, the use of neutralizing anti–SARS-CoV-2 monoclonal antibodies (mAbs) to confer a passive immunity appears attractive in KTRs. <b>Methods:</b> This retrospective monocentric cohort study was conducted between 1 January 2022 and 30 September 2022. All KTRs with a weak antibody response one month after three doses of mRNA vaccine (anti spike IgG < 264 (BAU/mL)) have received tixagevimab-cilgavimab in pre-exposure (group 1), post-exposure (group 2) or no specific treatment (group 3). We compared COVID-19 symptomatic hospitalizations, including intensive care unit hospitalizations, oxygen therapy, and death, between the three groups. <b>Results:</b> A total of 418 KTRs had SARS-CoV-2 infection in 2022. During the study period, we included 112 KTRs in group 1, 40 KTRs in group 2, and 27 KTRs in group 3. The occurrence of intensive care unit hospitalization, oxygen therapy, and COVID-19 death was significantly increased in group 3 compared to group 1 or 2. In group 3, 5 KTRs (18.5%) were admitted to the intensive care unit, 7 KTRs (25.9%) needed oxygen therapy, and 3 KTRs (11.1%) died. Patients who received tixagevimab-cilgavimab pre- or post-exposure had similar outcomes. <b>Conclusions:</b> This retrospective real-life study supports the relative effectiveness of tixagevimab-cilgavimab on COVID-19 infection caused by Omicron, used as a pre- or post-exposure therapy. The continued evolution of Omicron variants has made tixagevimab-cilgavimab ineffective and reinforces the need for new therapeutic monoclonal antibodies for COVID-19 active on new variants.https://www.mdpi.com/1999-4915/16/3/381COVID-19monoclonal antibodiesSARS-CoV-2kidney transplantation |
| spellingShingle | Anais Romero Charlotte Laurent Ludivine Lebourg Veronique Lemée Mélanie Hanoy Frank Le Roy Steven Grange Mathilde Lemoine Dominique Guerrot Dominique Bertrand Anti SARS-CoV-2 Monoclonal Antibodies in Pre-Exposure or Post-Exposure in No- or Weak Responder to Vaccine Kidney Transplant Recipients: Is One Strategy Better than Another? Viruses COVID-19 monoclonal antibodies SARS-CoV-2 kidney transplantation |
| title | Anti SARS-CoV-2 Monoclonal Antibodies in Pre-Exposure or Post-Exposure in No- or Weak Responder to Vaccine Kidney Transplant Recipients: Is One Strategy Better than Another? |
| title_full | Anti SARS-CoV-2 Monoclonal Antibodies in Pre-Exposure or Post-Exposure in No- or Weak Responder to Vaccine Kidney Transplant Recipients: Is One Strategy Better than Another? |
| title_fullStr | Anti SARS-CoV-2 Monoclonal Antibodies in Pre-Exposure or Post-Exposure in No- or Weak Responder to Vaccine Kidney Transplant Recipients: Is One Strategy Better than Another? |
| title_full_unstemmed | Anti SARS-CoV-2 Monoclonal Antibodies in Pre-Exposure or Post-Exposure in No- or Weak Responder to Vaccine Kidney Transplant Recipients: Is One Strategy Better than Another? |
| title_short | Anti SARS-CoV-2 Monoclonal Antibodies in Pre-Exposure or Post-Exposure in No- or Weak Responder to Vaccine Kidney Transplant Recipients: Is One Strategy Better than Another? |
| title_sort | anti sars cov 2 monoclonal antibodies in pre exposure or post exposure in no or weak responder to vaccine kidney transplant recipients is one strategy better than another |
| topic | COVID-19 monoclonal antibodies SARS-CoV-2 kidney transplantation |
| url | https://www.mdpi.com/1999-4915/16/3/381 |
| work_keys_str_mv | AT anaisromero antisarscov2monoclonalantibodiesinpreexposureorpostexposureinnoorweakrespondertovaccinekidneytransplantrecipientsisonestrategybetterthananother AT charlottelaurent antisarscov2monoclonalantibodiesinpreexposureorpostexposureinnoorweakrespondertovaccinekidneytransplantrecipientsisonestrategybetterthananother AT ludivinelebourg antisarscov2monoclonalantibodiesinpreexposureorpostexposureinnoorweakrespondertovaccinekidneytransplantrecipientsisonestrategybetterthananother AT veroniquelemee antisarscov2monoclonalantibodiesinpreexposureorpostexposureinnoorweakrespondertovaccinekidneytransplantrecipientsisonestrategybetterthananother AT melaniehanoy antisarscov2monoclonalantibodiesinpreexposureorpostexposureinnoorweakrespondertovaccinekidneytransplantrecipientsisonestrategybetterthananother AT frankleroy antisarscov2monoclonalantibodiesinpreexposureorpostexposureinnoorweakrespondertovaccinekidneytransplantrecipientsisonestrategybetterthananother AT stevengrange antisarscov2monoclonalantibodiesinpreexposureorpostexposureinnoorweakrespondertovaccinekidneytransplantrecipientsisonestrategybetterthananother AT mathildelemoine antisarscov2monoclonalantibodiesinpreexposureorpostexposureinnoorweakrespondertovaccinekidneytransplantrecipientsisonestrategybetterthananother AT dominiqueguerrot antisarscov2monoclonalantibodiesinpreexposureorpostexposureinnoorweakrespondertovaccinekidneytransplantrecipientsisonestrategybetterthananother AT dominiquebertrand antisarscov2monoclonalantibodiesinpreexposureorpostexposureinnoorweakrespondertovaccinekidneytransplantrecipientsisonestrategybetterthananother |